Longeviti Neuro Solutions, a neurotechnology company focused on advancing innovative solutions that unlock post-operative ultrasound access to the brain, today announced the launch of two strategic initiatives, ClearFit AI™, a Brain Ultrasound Interface (BUI). Together, these technologies create a persistent acoustic interface to the brain, enabling real-time bedside imaging and supporting future advances in AI-assisted neurosurgical care. The ClearFit AI™ platform combi

ENvue Medical, Inc. (NASDAQ: FEED) (“ENvue,” “ENvue Medical” or the “Company”), a commercial-stage medical device company focused on real-time guided bedside feeding tube placement, today announced the successful development and demonstration of the first prototype of ENvue Drive™, which the Company believes is the first next-generation robotic-assisted tool built within the ENvue electromagnetic navigation platform ecosystem, designed to integrate ar

Leo Cancer Care, the medical technology company working to reinvent how patients are imaged and treated by designing systems around the body’s natural upright position, today announced the close of an oversubscribed $65 million Series D financing. The round was led by Silicon Valley’s Yu Galaxy and welcomes new investors including Eventide Asset Management, alongside continued support from the company’s existing investors. Leading cancer institutions are already ad

Miach Orthopaedics, Inc., a company transforming the treatment of anterior cruciate ligament (ACL) tears from reconstruction to restoration with the Bridge-Enhanced ACL Restoration (BEAR®) Implant, today announced it will present two-year outcomes from the first 200 patients enrolled in the Bridge Registry at the American Orthopaedic Society for Sports Medicine (AOSSM) Annual Meeting, July 8-11 in Seattle. The presentation will highlight how evolved fixation and suture technique

Novartis today announced that the European Commission (EC) has approved Itvisma® (onasemnogene abeparvovec) for the treatment of children two years and older, teens and adults living with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the survival motor neuron 1 (SMN1) gene. With this approval, Itvisma becomes the first and only gene replacement therapy currently approved for this broad SMA population in the European Union. Itvisma is uniquely designed

SkylineDx,  innovative diagnostics company specializing in the research and development of molecular diagnostics for dermatology and oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to Merlin CP-GEP¹ , a clinicopathologic gene expression profile (CP-GEP) test designed to support risk assessment and clinical decision-making in patients with early-stage cutaneous melanoma. The FDA's Breakthrough Device

Aurenar, developer of a non-invasive neuromodulation platform for patients in intensive care, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its V-Link™ System for the reduction of cerebral vasospasm in adults with aneurysmal subarachnoid hemorrhage (aSAH). The designation applies to the use of V-Link in adult patients (22 years of age and older) with aSAH as an adjunct to clinical management to reduce the incidence of cer

Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the successful completion of the first procedures using its MWA technology in Vietnam and Argentina. In Vietnam, the first clinical case using the Company's MWA technology was completed at Lac Viet Friendship Hospital on June 18. The procedure was performed by Dr. Dinh Xuan Ha, Dep

Olympus Corporation (Olympus), a global MedTech company committed to advancing endoscopy-enabled care, today announced a reseller agreement with First Nation Group, a premier Service-Disabled Veteran-Owned Small Business (SDVOSB), Veteran-Owned Small Business (VOSB), and Small Business distributor serving federal healthcare customers nationwide.  Under the agreement, First Nation Group will serve as an authorized SDVOSB reseller for Olympus America Inc. (OAI), providing federal

CereVasc, Inc., a clinical-stage medical device company developing novel, minimally invasive treatments for neurological diseases, announced it has completed patient enrollment in its STRIDE pivotal trial evaluating the investigational eShunt System in patients with normal pressure hydrocephalus (NPH). With patient enrollment complete at 32 clinical sites, STRIDE is progressing through remaining treatment and follow-up activities for consented patients, keeping the company on track